Skip to main content

Vyant Bio, Inc. (VYNT)

NASDAQ: VYNT · IEX Real-Time Price · USD
2.23
+0.06 (2.77%)
After-hours:Oct 22, 2021 5:43 PM EDT
2.17
-0.02 (-0.91%)
At close: Oct 22, 4:00 PM
Market Cap62.90M
Revenue (ttm)5.05M
Net Income (ttm)-16.67M
Shares Out28.99M
EPS (ttm)-1.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume67,017
Open2.17
Previous Close2.19
Day's Range2.14 - 2.20
52-Week Range2.11 - 17.50
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings DateNov 11, 2021

About VYNT

Vyant Bio, Inc. operates as a biotechnology drug discovery company. The company, through its subsidiary, StemoniX, develops and manufactures at-scale human induced pluripotent stem (iPS) cell-derived neural and cardiac screening platforms for drug discovery and development. StemoniX, through collaborations with drug discovery organizations, tests compounds in-house, creates cell-based disease models, and operationalizes custom human iPSC-derived disease models for high-throughput screening. The company, through its subsidiary, vivoPharm, offers...

IndustryBiotechnology
IPO DateApr 5, 2013
CEOJohn Roberts
Employees40
Stock ExchangeNASDAQ
Ticker SymbolVYNT
Full Company Profile

Financial Performance

In 2020, Vyant Bio's revenue was $5.75 million, a decrease of -21.27% compared to the previous year's $7.31 million. Losses were -$8.00 million, 19.3% more than in 2019.

Financial Statements

News

Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder

CHERRY HILL, NJ and TORONTO, CANADA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc., (Nasdaq: VYNT), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat...

2 months ago - GlobeNewsWire

Vyant Bio Announces Investor Conference Call and Webcast for Second Quarter 2021

CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule t...

2 months ago - GlobeNewsWire

Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids

CHERRY HILL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery technologies, announced today that its wholly...

3 months ago - GlobeNewsWire

Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update

Cherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnolo...

5 months ago - GlobeNewsWire

Vyant Bio to Present at BioNJ's 11th Annual BioPartnering Conference

CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technol...

5 months ago - GlobeNewsWire

3 Short Squeeze Candidates In The Health Care Sector

Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.

Other symbols:RXDXTHMO
5 months ago - Benzinga

Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small...

New collaboration mitigates risk in drug d iscovery process with artificial intelligence and in vitro “avatar” clinical trials

6 months ago - GlobeNewsWire

Vyant Bio Announces Newly Appointed Board of Directors

CHERRY HILL, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-bas...

6 months ago - GlobeNewsWire

Vyant Bio Announces Investor Webcast to Provide Updates Post Merger between Cancer Genetics and StemoniX

CHERRY HILL, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is a new force in drug discovery focused on integrating human-powered scientific and technology-base...

6 months ago - GlobeNewsWire

Cancer Genetics and StemoniX Announce Merger Closing

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

6 months ago - GlobeNewsWire

Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline o...

6 months ago - GlobeNewsWire

Cancer Genetics to Present at the Annual 33rd ROTH Conference

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...

7 months ago - GlobeNewsWire

Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief ...

7 months ago - GlobeNewsWire

Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

8 months ago - GlobeNewsWire

Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

8 months ago - GlobeNewsWire

Why AzurRx BioPharma, Usana Health Are Moving Today

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. ...

Other symbols:USNAABCL
8 months ago - Benzinga

CGIX Stock: Why Cancer Genetics Shares Are Rocketing Higher Today

Cancer Genetics said its board has approved the StemoniX merger, setting the stage for a March shareholder vote. In the wake of the move, investors drove up the CGIX stock price in Wednesday's premarket...

8 months ago - InvestorPlace

Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

8 months ago - GlobeNewsWire

Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market

RUTHERFORD, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announce...

8 months ago - GlobeNewsWire

Cancer Genetics to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright

RUTHERFORD, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief E...

9 months ago - GlobeNewsWire

SHAREHOLDER ALERT: WeissLaw LLP Investigates Cancer Genetics, Inc.

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. ("CGIX" or the "C...

11 months ago - PRNewsWire

Cancer Genetics Reports Third Quarter 2020 Financial Results

RUTHERFORD, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced toda...

11 months ago - GlobeNewsWire

Cancer Genetics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriter's Option to Purchase ...

Rutherford, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics” or “the Company”), a leader in drug discovery and preclinical oncology and immuno-oncology ser...

11 months ago - GlobeNewsWire

Cancer Genetics, Inc. Increases Previously Announced Bought Deal to $3.0 Million

Rutherford, N.J., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX) (“Cancer Genetics”), a leader in drug discovery and preclinical oncology and immuno-oncology services, announced ...

11 months ago - GlobeNewsWire